Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Short Interest Down 14.2% in December

Nautilus Biotechnology, Inc. (NASDAQ:NAUT - Get Free Report) was the recipient of a large decline in short interest during the month of December. As of December 31st, there was short interest totalling 1,030,000 shares, a decline of 14.2% from the December 15th total of 1,200,000 shares. Based on an average daily trading volume, of 131,000 shares, the short-interest ratio is presently 7.9 days. Approximately 1.8% of the shares of the company are short sold.

Institutional Trading of Nautilus Biotechnology

Hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC purchased a new stake in Nautilus Biotechnology in the 3rd quarter worth about $50,000. The Manufacturers Life Insurance Company bought a new position in Nautilus Biotechnology during the third quarter worth about $67,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Nautilus Biotechnology by 63.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 24,121 shares of the company's stock worth $69,000 after purchasing an additional 9,404 shares in the last quarter. MetLife Investment Management LLC bought a new stake in shares of Nautilus Biotechnology in the third quarter valued at approximately $87,000. Finally, Barclays PLC raised its position in shares of Nautilus Biotechnology by 79.6% in the third quarter. Barclays PLC now owns 106,174 shares of the company's stock valued at $303,000 after purchasing an additional 47,059 shares during the period. 50.71% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, The Goldman Sachs Group downgraded Nautilus Biotechnology from a "neutral" rating to a "sell" rating and decreased their price target for the company from $2.25 to $1.75 in a research report on Thursday, December 5th.

Nautilus Biotechnology Stock Down 2.1 %

NASDAQ NAUT traded down $0.04 during trading hours on Thursday, reaching $1.90. 68,207 shares of the company were exchanged, compared to its average volume of 139,801. The stock has a market capitalization of $238.56 million, a P/E ratio of -3.39 and a beta of 1.20. Nautilus Biotechnology has a 1 year low of $1.61 and a 1 year high of $3.12. The business's 50 day simple moving average is $2.05 and its 200-day simple moving average is $2.43.

Nautilus Biotechnology (NASDAQ:NAUT - Get Free Report) last issued its quarterly earnings results on Tuesday, October 29th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.04. During the same quarter in the previous year, the business posted ($0.13) EPS. As a group, sell-side analysts anticipate that Nautilus Biotechnology will post -0.57 earnings per share for the current year.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.